M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Name: M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
Published: 2023
License: Public Domain

FutureGen Biopharmaceutical (Beijing) Co., Ltd · 2023

ClinicalTrials.gov · Datasets · License: Public Domain · 2023

Open Source ↗

locally advanced unresectable or metastatic gastric cancer, locally advanced unresectable or metastatic gastroesophageal junction (gej) adenocarcinoma, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Related documents